TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. PRODUCT DEVELOPMENTS AND LAUNCHES BY MARKET PLAYERS PROMOTE MARKET GROWTH
2.5.2. PREVALENCE OF DIABETES AND CANCER
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGING INFERTILITY INCIDENCES
3.1.2. ASSISTED REPRODUCTIVE TECHNOLOGY ADOPTION
3.1.3. TECHNOLOGICAL ADVANCEMENTS
3.2. KEY RESTRAINTS
3.2.1. HIGH TREATMENT COSTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TEST TYPE
5.1. DNA FRAGMENTATION TECHNIQUE
5.2. OXIDATIVE STRESS ANALYSIS
5.3. MICROSCOPIC EXAMINATION
5.4. SPERM AGGLUTINATION
5.5. COMPUTER-ASSISTED SEMEN ANALYSIS
5.6. SPERM PENETRATION ASSAY
5.7. OTHER TEST TYPES
6. MARKET BY TREATMENT
6.1. ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY
6.2. MEDICATIONS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. NORTH AMERICA MALE INFERTILITY MARKET DRIVERS
7.1.3. NORTH AMERICA MALE INFERTILITY MARKET CHALLENGES
7.1.4. KEY PLAYERS IN NORTH AMERICA MALE INFERTILITY MARKET
7.1.5. COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.1.1. UNITED STATES MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.1.5.2. CANADA
7.1.5.2.1. CANADA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2. EUROPE
7.2.1. MARKET SIZE & ESTIMATES
7.2.2. EUROPE MALE INFERTILITY MARKET DRIVERS
7.2.3. EUROPE MALE INFERTILITY MARKET CHALLENGES
7.2.4. KEY PLAYERS IN EUROPE MALE INFERTILITY MARKET
7.2.5. COUNTRY ANALYSIS
7.2.5.1. UNITED KINGDOM
7.2.5.1.1. UNITED KINGDOM MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.2. GERMANY
7.2.5.2.1. GERMANY MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.3. FRANCE
7.2.5.3.1. FRANCE MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.4. ITALY
7.2.5.4.1. ITALY MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.5. SPAIN
7.2.5.5.1. SPAIN MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.6. BELGIUM
7.2.5.6.1. BELGIUM MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.7. POLAND
7.2.5.7.1. POLAND MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.2.5.8. REST OF EUROPE
7.2.5.8.1. REST OF EUROPE MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3. ASIA-PACIFIC
7.3.1. MARKET SIZE & ESTIMATES
7.3.2. ASIA-PACIFIC MALE INFERTILITY MARKET DRIVERS
7.3.3. ASIA-PACIFIC MALE INFERTILITY MARKET CHALLENGES
7.3.4. KEY PLAYERS IN ASIA-PACIFIC MALE INFERTILITY MARKET
7.3.5. COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.1.1. CHINA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.2. JAPAN
7.3.5.2.1. JAPAN MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.3. INDIA
7.3.5.3.1. INDIA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.4. SOUTH KOREA
7.3.5.4.1. SOUTH KOREA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.5. INDONESIA
7.3.5.5.1. INDONESIA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.6. THAILAND
7.3.5.6.1. THAILAND MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.7. VIETNAM
7.3.5.7.1. VIETNAM MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.8. AUSTRALIA & NEW ZEALAND
7.3.5.8.1. AUSTRALIA & NEW ZEALAND MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.3.5.9. REST OF ASIA-PACIFIC
7.3.5.9.1. REST OF ASIA-PACIFIC MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.4. REST OF WORLD
7.4.1. MARKET SIZE & ESTIMATES
7.4.2. REST OF WORLD MALE INFERTILITY MARKET DRIVERS
7.4.3. REST OF WORLD MALE INFERTILITY MARKET CHALLENGES
7.4.4. KEY PLAYERS IN REST OF WORLD MALE INFERTILITY MARKET
7.4.5. REGIONAL ANALYSIS
7.4.5.1. LATIN AMERICA
7.4.5.1.1. LATIN AMERICA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
7.4.5.2. MIDDLE EAST & AFRICA
7.4.5.2.1. MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS
8.2. COMPANY PROFILES
8.2.1. ADVACARE PHARMA USA
8.2.1.1. COMPANY OVERVIEW
8.2.1.2. PRODUCTS / SERVICES LIST
8.2.2. ANDROLOGY SOLUTIONS
8.2.2.1. COMPANY OVERVIEW
8.2.2.2. PRODUCTS / SERVICES LIST
8.2.3. AYTU BIOPHARMA
8.2.3.1. COMPANY OVERVIEW
8.2.3.2. PRODUCTS / SERVICES LIST
8.2.3.3. STRENGTHS & CHALLENGES
8.2.4. BAYER GROUP
8.2.4.1. COMPANY OVERVIEW
8.2.4.2. PRODUCTS / SERVICES LIST
8.2.4.3. STRENGTHS & CHALLENGES
8.2.5. CAERUS BIOTECH
8.2.5.1. COMPANY OVERVIEW
8.2.5.2. PRODUCTS / SERVICES LIST
8.2.6. CINNAGEN CO
8.2.6.1. COMPANY OVERVIEW
8.2.6.2. PRODUCTS / SERVICES LIST
8.2.6.3. STRENGTHS & CHALLENGES
8.2.7. EMD SERONO INC (MERCK SERONO)
8.2.7.1. COMPANY OVERVIEW
8.2.7.2. PRODUCTS / SERVICES LIST
8.2.7.3. STRENGTHS & CHALLENGES
8.2.8. ENDO INTERNATIONAL PLC
8.2.8.1. COMPANY OVERVIEW
8.2.8.2. PRODUCTS / SERVICES LIST
8.2.8.3. STRENGTHS & CHALLENGES
8.2.9. HALOTECH DNA
8.2.9.1. COMPANY OVERVIEW
8.2.9.2. PRODUCTS / SERVICES LIST
8.2.10. LABORATORY CORPORATION OF AMERICA HOLDINGS
8.2.10.1. COMPANY OVERVIEW
8.2.10.2. PRODUCTS / SERVICES LIST
8.2.10.3. STRENGTHS & CHALLENGES
8.2.11. SANOFI
8.2.11.1. COMPANY OVERVIEW
8.2.11.2. PRODUCTS / SERVICES LIST
8.2.11.3. STRENGTHS & CHALLENGES
8.2.12. SCSA DIAGNOSTICS
8.2.12.1. COMPANY OVERVIEW
8.2.12.2. PRODUCTS / SERVICES LIST
8.2.13. THERAMEX
8.2.13.1. COMPANY OVERVIEW
8.2.13.2. PRODUCTS / SERVICES LIST
8.2.14. VITROLIFE
8.2.14.1. COMPANY OVERVIEW
8.2.14.2. PRODUCTS / SERVICES LIST
8.2.14.3. STRENGTHS & CHALLENGES
8.2.15. ZYDUS LIFESCIENCES LTD (CADILA HEALTHCARE LTD)
8.2.15.1. COMPANY OVERVIEW
8.2.15.2. PRODUCTS / SERVICES LIST
8.2.15.3. STRENGTHS & CHALLENGES
TABLE 1: MARKET SNAPSHOT – MALE INFERTILITY
TABLE 2: GLOBAL MALE INFERTILITY MARKET, BY TEST TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GLOBAL MALE INFERTILITY MARKET, BY TEST TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: GLOBAL DNA FRAGMENTATION TECHNIQUE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GLOBAL DNA FRAGMENTATION TECHNIQUE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: GLOBAL OXIDATIVE STRESS ANALYSIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GLOBAL OXIDATIVE STRESS ANALYSIS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: GLOBAL MICROSCOPIC EXAMINATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: GLOBAL MICROSCOPIC EXAMINATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: GLOBAL SPERM AGGLUTINATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: GLOBAL SPERM AGGLUTINATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: GLOBAL COMPUTER-ASSISTED SEMEN ANALYSIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: GLOBAL COMPUTER-ASSISTED SEMEN ANALYSIS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 14: GLOBAL SPERM PENETRATION ASSAY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 15: GLOBAL SPERM PENETRATION ASSAY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 16: GLOBAL OTHER TEST TYPES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 17: GLOBAL OTHER TEST TYPES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 18: GLOBAL MALE INFERTILITY MARKET, BY TREATMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 19: GLOBAL TREATMENT MARKET, BY TREATMENT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 20: GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 21: GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 22: GLOBAL MEDICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 23: GLOBAL MEDICATIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 24: GLOBAL MALE INFERTILITY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 25: GLOBAL MALE INFERTILITY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 26: NORTH AMERICA MALE INFERTILITY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 27: NORTH AMERICA MALE INFERTILITY MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 28: KEY PLAYERS OPERATING IN NORTH AMERICA MALE INFERTILITY MARKET
TABLE 29: EUROPE MALE INFERTILITY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 30: EUROPE MALE INFERTILITY MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 31: KEY PLAYERS OPERATING IN EUROPE MALE INFERTILITY MARKET
TABLE 32: ASIA-PACIFIC MALE INFERTILITY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 33: ASIA-PACIFIC MALE INFERTILITY MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 34: KEY PLAYERS OPERATING IN ASIA-PACIFIC MALE INFERTILITY MARKET
TABLE 35: REST OF WORLD MALE INFERTILITY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 36: REST OF WORLD MALE INFERTILITY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 37: KEY PLAYERS OPERATING IN REST OF WORLD MALE INFERTILITY MARKET
TABLE 38: LIST OF MERGERS & ACQUISITIONS
TABLE 39: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 40: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 41: LIST OF BUSINESS EXPANSIONS
| ※参考情報 男性不妊症は、男性の生殖能力が低下することによって、妊娠に至らない状態を指します。この状態は、様々な要因によって引き起こされ、一般的に精子の生成や運動能力、精子の質などに問題があることが多いです。日本を含む多くの国では、カップルの不妊の原因の約40%から50%が男性に起因することが知られています。 男性不妊症の原因にはいくつかの種類があります。まずは、精子の生成に関する問題です。これは、精巣で精子が正しく生成されない場合が多く、ホルモン異常や遺伝的要因が関わることがあります。また、精子の数が少ない「乏精子症」、運動能力が低下している「精子無力症」、精子の形に異常がある「奇形精子症」などの異常が考えられます。 次に、精子が正常に運ばれない場合です。これには、精管が閉塞している、または欠損しているといった解剖学的な問題が含まれます。これにより、精子が射精されることができず、妊娠する可能性が低くなります。また、性機能障害や心理的要因も関連し、勃起不全や射精障害も男性不妊症の原因となります。 さらに、生活習慣や環境因子が男性不妊症に影響を及ぼすこともあります。喫煙、過度の飲酒、肥満、ストレス、熱環境(サウナやホットバスの多用)などが精子の質を低下させることが明らかになっています。加えて、一部の薬物や化学物質への暴露も、不妊症の一因とされています。 治療法は、その原因に応じてさまざまです。ホルモン異常が原因であれば、ホルモン療法が行われることがあります。精子の生成に関する問題があれば、ライフスタイルの改善や栄養管理が奨励されることもあります。また、閉塞が原因の場合には、外科的手術が選択肢となることがあります。 最近では、さまざまな補助生殖技術が普及してきています。例えば、顕微授精(ICSI)は、選ばれた精子を卵子に直接注入する方法であり、精子の質が低い場合でも妊娠の可能性を高めることができます。さらに、精子凍結は、治療が必要な男性にとって有効な選択肢となっており、リスクがある職業や治療を受ける前に精子を保存するケースが増えています。 加えて、最近の研究では、男性不妊症のメカニズムがより明らかになりつつあります。遺伝子解析や生殖機能に関する新しいマーカーの発見が進められており、個々の患者に最適な治療が提供できる可能性が高まっています。このような研究により、将来的にはより効果的な治療法が確立されることが期待されています。 男性不妊症は、医学的な観点だけでなく、心理的な面でも影響を及ぼします。パートナーとのコミュニケーションや、自分自身の感情を整理することが重要です。さらに、医療従事者との連携が大切であり、カウンセリングや支援を受けることも有益です。 男性不妊症は、個人だけでなく、カップル全体に影響を与える問題です。適切な診断と治療は、カップルの希望する家族の形成への第一歩となります。早期の専門家への相談が推奨され、適切な情報とサポートを受けることが重要です。このような取り組みを通じて、男性不妊症に対する理解と対応が進むことが期待されています。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

